SCHEDULE 13G/A: Suvretta Capital Management and Affiliates Update Passive Stake in Kura Oncology to 6.7%

Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have filed an amended Schedule 13G, reporting a combined passive beneficial ownership of 6.7% in Kura Oncology, Inc. as of December 31, 2024.

Summary

• Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen collectively reported beneficial ownership of Kura Oncology, Inc. common stock.
• As of December 31, 2024, Suvretta Capital Management, LLC and Aaron Cowen each beneficially owned 5,198,189 shares, representing 6.7% of Kura Oncology's common stock.
• Averill Master Fund, Ltd. beneficially owned 4,592,673 shares, representing 5.9% of Kura Oncology's common stock.
• The filing is an Amendment No. 4 to a Schedule 13G, indicating an update to their previously reported passive investment.
• The reported shares include common stock directly held by Averill Master Fund, Ltd., which may be indirectly owned by Suvretta Capital Management, LLC and Aaron Cowen.
• The filing notes the existence of pre-funded warrants with an exercise price of $0.001 per share, subject to a beneficial ownership limitation of 9.99% (or up to 19.99% with notice), meaning they are not all presently exercisable.

Sentiment

Score: 5

Explanation: Neutral. This is a routine regulatory filing updating passive ownership, providing factual information without explicit positive or negative operational news.

Positives

• Significant institutional investor (Suvretta Capital Management) maintains a substantial passive stake in Kura Oncology, indicating continued confidence in the company.

Risks

• The exercise of pre-funded warrants is subject to a beneficial ownership limitation, which could restrict immediate full conversion and impact the total outstanding shares if the limit is increased.

Future Outlook

NA

Industry Context

This filing reflects a passive investment by a significant institutional fund in Kura Oncology, a biotechnology company. Such filings are common for funds that take substantial, non-controlling positions in public companies, often signaling long-term interest in the sector or specific company's prospects.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.

Key Dates

Keywords

Kura Oncology, Suvretta Capital Management, Averill Master Fund, Aaron Cowen, Schedule 13G/A, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, Biotechnology, Pharmaceuticals